Education
About Us
Working with TipRanks
Follow Us
Generate Biomedicines, Inc. (GENB)
NASDAQ:GENB
GENB Stock Chart & Stats
$12.72
$0.51(4.18%)
―
--
Day’s Range― - ―
52-Week Range$11.00 - $15.32
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding127,450,200
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GENB FAQ
What was Generate Biomedicines, Inc.’s price range in the past 12 months?
Generate Biomedicines, Inc. lowest stock price was $11.00 and its highest was $15.32 in the past 12 months.
What is Generate Biomedicines, Inc.’s market cap?
Currently, no data Available
When is Generate Biomedicines, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Generate Biomedicines, Inc.’s earnings last quarter?
Currently, no data Available
Is Generate Biomedicines, Inc. overvalued?
According to Wall Street analysts Generate Biomedicines, Inc.’s price is currently Undervalued.
Does Generate Biomedicines, Inc. pay dividends?
Generate Biomedicines, Inc. does not currently pay dividends.
What is Generate Biomedicines, Inc.’s EPS estimate?
Generate Biomedicines, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Generate Biomedicines, Inc. have?
Generate Biomedicines, Inc. has 127,450,200 shares outstanding.
What happened to Generate Biomedicines, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Generate Biomedicines, Inc.?
Currently, no hedge funds are holding shares in GENB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Generate Biomedicines, Inc.
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts.